Information on how to access Fragmin® (dalteparin sodium) prescribing information and adverse event reporting can be found at the bottom of the page.
(with medical conditions including, but not limited to: congestive cardiac failure (NYHA class III or IV), acute respiratory failure or acute infection, who also have a predisposing risk factor for venous thromboembolism such as age over 75 years, obesity, cancer or previous history of VTE.)
Leizorovicz A et al. Circulation 2004;110:874–8791.
An international, multicentre, randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of Fragmin for the prevention of venous thromboembolism (VTE) in acutely ill medical patients (N=3,706). Patients were assigned to receive either s.c. Fragmin (5,000 IU o.d.; n=1,518) or placebo (n=1,473) for 14 days and were followed up for 90 days.
Incidence of VTE by Day 21.
Mortality by Days 14, 21 and 90; symptomatic deep vein thrombosis (DVT) or asymptomatic DVT at Day 21; major and minor bleeding; drug-related allergic reactions; thrombocytopenia by Day 21; symptomatic VTE at Day 90.
Patients treated with Fragmin had a lower incidence of VTE at Day 21 compared with patients treated with placebo (2.77% vs. 4.96%, P=0.0015). This observed benefit was maintained at 90 days. The incidence of proximal DVT by Day 21 was lower among patients receiving Fragmin than those receiving placebo (symptomatic: 0.11% vs 0.40%; asymptomatic: 1.79% vs. 3.65%). 2 placebo and no Fragmin patients had fatal pulmonary embolism ( PE) by Day 21. There was no significant difference in mortality between both groups at 14, 21 or 90 days. Patients treated with Fragmin had a higher incidence of major bleeding than patients treated with placebo (0.49% vs. 0.16%, P=0.15).
Fragmin reduced clinically important VTE with a low risk of bleeding in acutely ill medical patients.
Kucher et al. Arch Intern Med 2005;165:341–3452.
Retrospective analysis of the PREVENT trial to determine if fixed rather than weight-based dosages of Fragmin are as effective and safe for the prevention of VTE in obese and elderly medical patients. Obese patients (n=1,118) and elderly patients (n=1,226) received either Fragmin (5,000 IU, o.d.) or placebo.
Symptomatic VTE, fatal PE, sudden death or asymptomatic proximal DVT by Day 21.
In obese patients, primary end point incidence was higher in those treated with placebo rather than Fragmin (4.3% vs. 2.8%), however, no difference was observed between obese and non-obese patients who reached the primary endpoint receiving either treatment. In elderly patients (≥ 75 years old), primary end point incidence was higher in those treated with placebo rather than Fragmin (8.0% vs. 4.2%). The incidence of PE and DVT was higher in elderly patients compared to younger patients; this was the case in both the Fragmin and placebo groups.
Fragmin did not increase incidence of major bleeding events by Day 21 in obese (0% vs. 0.7% placebo; P=0.99) and in elderly (1.1% vs. 0.7% placebo; P=0.12) patients.
A fixed dose of Fragmin (5,000 IU, o.d.) was as effective in VTE prevention at Day 21 in obese vs. non-obese and in elderly vs. younger hospitalised patients. With respect to safety, no significant differences in mortality or major bleeding were observed between Fragmin and placebo treated patients, in both the obese and elderly subgroups.
Fragmin (dalteparin sodium) 10,000 IU/0.4ml solution for injection
Fragmin (dalteparin sodium) 10,000 IU/1 ml solution for injection
Fragmin (dalteparin sodium) 10,000 IU/4ml solution for injection
Fragmin (dalteparin sodium) 100,000 IU / 4ml Multidose Vial solution for injection
Fragmin (dalteparin sodium) 12,500 IU/0.5ml solution for injection
Fragmin (dalteparin sodium) 15,000 IU/0.6ml solution for injection
Fragmin (dalteparin sodium) 18,000 IU/0.72ml solution for injection
Fragmin (dalteparin sodium) 2500 IU solution for injection
Fragmin (dalteparin sodium) 5000 IU solution for injection
Fragmin (dalteparin sodium) 7,500 IU/0.3 ml solution for injection
Fragmin (dalteparin sodium) Graduated Syringe 10,000 IU/ml Solution for Injection
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
OK, We will need you to sign in before we can determine if you are aligned with a Pﬁzer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?